Free Trial
NASDAQ:CAN

Canaan (CAN) Stock Price, News & Analysis

$1.03
+0.05 (+4.69%)
(As of 12:57 PM ET)
Today's Range
$0.98
$1.05
50-Day Range
$0.85
$1.22
52-Week Range
$0.75
$3.50
Volume
2.38 million shs
Average Volume
13.88 million shs
Market Capitalization
$289.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.25

Canaan MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
311.3% Upside
$4.25 Price Target
Short Interest
Healthy
8.84% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.90 out of 5 stars

Computer And Technology Sector

402nd out of 568 stocks

Semiconductors & Related Devices Industry

63rd out of 87 stocks

CAN stock logo

About Canaan Stock (NASDAQ:CAN)

Canaan Inc. engages in the research, design, and sale of integrated circuit (IC) final mining equipment products by integrating IC products for bitcoin mining and related components in the People's Republic of China. It is also involved in the assembly and distribution of mining equipment and spare parts. The company has operations in the United States, Australia, Kazakhstan, Hong Kong, Canada, Mainland China, Thailand, Sweden, and internationally. Canaan Inc. was founded in 2013 and is based in Singapore.

CAN Stock Price History

CAN Stock News Headlines

NYSE biotech company's drug could be as revolutionary as penicillin!
NV-387 could be a single drug to treat all of the "tripledemic" viruses and more! See how NV-387 could be highly valuable for preparedness against novel viral epidemics and pandemics all while building shareholder value for this growing biotech company
Canaan Gets Left Behind In Latest Crypto Bull Run
NYSE biotech company's drug could be as revolutionary as penicillin!
NV-387 could be a single drug to treat all of the "tripledemic" viruses and more! See how NV-387 could be highly valuable for preparedness against novel viral epidemics and pandemics all while building shareholder value for this growing biotech company
Q1 2024 Canaan Inc Earnings Call
15 Biggest Publicly Traded Bitcoin Companies
See More Headlines
Receive CAN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Canaan and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/17/2024
Today
7/08/2024
Next Earnings (Estimated)
9/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Semiconductors & related devices
Sub-Industry
N/A
Current Symbol
NASDAQ:CAN
Fax
N/A
Employees
541
Year Founded
2013

Price Target and Rating

Average Stock Price Target
$4.25
High Stock Price Target
$5.50
Low Stock Price Target
$3.00
Potential Upside/Downside
+331.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-414,150,000.00
Net Margins
-192.95%
Pretax Margin
-218.14%

Debt

Sales & Book Value

Annual Sales
$211.48 million
Book Value
$1.49 per share

Miscellaneous

Free Float
279,409,000
Market Cap
$276.16 million
Optionable
Optionable
Beta
3.09

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

CAN Stock Analysis - Frequently Asked Questions

How have CAN shares performed this year?

Canaan's stock was trading at $2.31 on January 1st, 2024. Since then, CAN shares have decreased by 55.3% and is now trading at $1.0334.
View the best growth stocks for 2024 here
.

How were Canaan's earnings last quarter?

Canaan Inc. (NASDAQ:CAN) issued its quarterly earnings data on Friday, May, 17th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.44. The business earned $35.09 million during the quarter, compared to the consensus estimate of $30.10 million. Canaan had a negative trailing twelve-month return on equity of 75.57% and a negative net margin of 192.95%.

Does Canaan have any subsidiaries?

Canaan subsidiaries include these companies: Proof of Existence, Canaan Bright Sight Co. Ltd., Canaan Convey Co. Ltd., Canaan Creative Co. Ltd., Canaan Creative (HK) Holdings Limited, Canaan Creative International PTE. Ltd., Canaan Creative (SH) Co. Ltd., and others.

When did Canaan IPO?

Canaan (CAN) raised $100 million in an initial public offering (IPO) on Thursday, November 21st 2019. The company issued 10,000,000 shares at a price of $9.00-$11.00 per share. Citigroup, China Renaissance and CMBI served as the underwriters for the IPO and Galaxy Digital Advisors, Huatai Securities and Tiger Brokers were co-managers.

How do I buy shares of Canaan?

Shares of CAN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CAN) was last updated on 7/8/2024 by MarketBeat.com Staff

From Our Partners